secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001628280-21-024551
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Dr. June Almenoff and Mitchell Chan as independent directors
--------------------------------------------------------------------------------

- Dr. June Almenoff appointed effective Nov 10, 2021; replaces Dr. Suzanne Bruhn.
- Mitchell Chan appointed effective Dec 1, 2021; replaces Philip Gutry per Armistice Capital agreement.
- Dr. Almenoff is CMO at RedHill Biopharma, ex-CMO of Furiex (acquired by Actavis), and former GSK executive.
- Mr. Chan ex-CFO of Viela Bio (led $750M+ capital raises and $3.1B Horizon acquisition), prior roles at AstraZeneca and Genentech-Roche.
- Chan will chair Audit Committee and serve on Compensation Committee; both are independent directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/0001628280-21-024551-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828021024551/avtx-20211201.htm
  HTML page:      https://secwatch.observer/filing/0001628280-21-024551

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer